BIODESIX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIODESIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 4.00K shares, a 300.00% increase year-over-year.
- BIODESIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 13.00K shares, a 116.67% increase year-over-year.
- BIODESIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 8.00K shares, a 92.52% decline year-over-year.
- BIODESIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 6.00K shares, a 33.33% decline year-over-year.
- BIODESIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 31.00K shares, a 74.80% decline from fiscal 2023.
- BIODESIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 123.00K shares, a 67.97% decline from fiscal 2022.
- BIODESIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 384.00K shares, a 94017.65% increase from fiscal 2021.
- BIODESIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 408.00 shares, a 99.89% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2024-12-31 | 4.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 31.00K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 13.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | 28.00K shares derived: sum of 4 quarters · filed 2024-11-01 |
| 2024-06-30 | 8.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 21.00K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 6.00K shares 10-Q · filed 2024-05-08 | 120.00K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 1.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | 123.00K shares 10-K · filed 2024-03-01 |
| 2023-09-30 | 6.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 282.00K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 107.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 370.00K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 9.00K shares 10-Q · filed 2023-05-11 | 286.00K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 160.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 384.00K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 94.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -171.59K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 23.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -235.59K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 107.00K shares 10-Q · filed 2022-05-11 | -101.59K shares derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | -395.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | 408.00 shares 10-K · filed 2022-03-14 |
| 2021-09-30 | 30.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 729.00K shares derived: sum of 4 quarters · filed 2021-11-15 |
| 2021-06-30 | 157.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | |
| 2021-03-31 | 209.00K shares 10-Q · filed 2021-05-11 | |
| 2020-12-31 | 333.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | 368.00K shares 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |